BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an ...

2025 年 7 月 25 日，华宇元典于公司成立9周年纪念日当天下午，在东升科技园公司现场举办了“华宇元典AI开放日”活动。现场汇聚法律界同仁、行业伙伴，活动全程进行了线上直播，线上线下的伙伴们一同回顾了元典九载发展历程，探讨AI与法律的深度融合，并 ...

Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved ...

Amicus Therapeutics (FOLD) reported Q3 results that caught investors’ attention, posting GAAP profitability along with solid revenue gains from its rare disease therapies. Global expansion and ...

The Food and Drug Administration has changed its tune on an experimental drug for a deadly rare disease, withdrawing a request that the company developing it run another clinical trial. The unusual ...

Amicus Therapeutics aims to position its experimental Pompe disease treatment as the new standard of care, supplanting a therapy from Sanofi. But securing approval will require explaining to ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

Rare disease has always been Amicus Therapeutics’ focus, but in recent years the company adjusted how it aimed to treat such disorders, a shift that followed a $100 million acquisition of a gene ...

Receive essential Court news every morning. The premier source for Supreme Court news, analysis, and data since 2002. Independent and non-partisan. © 2026 SCOTUSblog ...